Acute kidney
injury therapeutic pipeline is likely to grow on account of increasing incidence
of diabetes and high blood pressure, in people, resulting in increasing prevalence
of acute kidney injury, globally. Low market penetration, due to presence of
limited number of companies making an analog and increasing health awareness
among people are few other factors contributing to the growth of acute kidney
injury therapeutic pipeline. According to the Centers for Disease Control and
Prevention, women (15.93%) are more likely to have stages 1 to 4 of acute
kidney injury than men (13.52%). It is also more common among African Americans
(17.01%) and Mexican Americans (15.29%) than in Caucasians (13.99%).
Explore Report at: https://www.psmarketresearch.com/market-analysis/acute-kidney-injury-therapeutic-pipeline-analysis
Acute kidney
injury is a serious condition which includes kidney damage or failure. This
results in building up of waste products in blood, due to which the balance of
fluids in the body gets disturbed, in turn affecting several other organs
including heart, lungs and brain. Acute kidney injury is caused due to the slow
flow of blood due to conditions such as low blood pressure, allergic reactions,
organ failure, heart diseases, blood loss and overuse of medicines. Sepsis,
cancer, vasculitis, interstitial nephritis, scleroderma and glomerulonephritis
cause direct damage to kidney which can also result in the development of acute
kidney injury. Blockage of urinary tract due to several conditions such as kidney
stones or blood clots in the tract can also result in acute kidney failure. The
most common signs and symptoms of acute kidney injury include nausea, shortness
of breath, swelling in legs and around eyes, less urination, fatigue and chest
pain. Acute kidney injury is diagnosed by measuring the urine output, measuring
glomerular filtration rate, blood tests, urine tests, imaging tests and kidney
biopsy. Acute kidney injury is treated by treating the root cause of the
disease in an individual. Severe cases require dialysis to improve kidney
function until the kidneys do not recover or are transplanted.
Some of the leading companies having a pipeline of acute kidney injury therapeutics include Baxter Healthcare Corporation, Angion Biomedica Corp., AM-Pharma BV, Sentien Biotechnologies, Inc., F. Hoffmann-La Roche Ltd., Evotec AG, NephroGenex, Inc., G1 Therapeutics, Inc., Alloksys Life Sciences BV, DiaMedica Therapeutics, Inc.
No comments:
Post a Comment